Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers for Chemotherapy in Advanced NSCLC
NCT02145078Terminated
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jun 2014
- Primary completion
- Jun 2015
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Open-label, single-arm trial of gemcitabine, pemetrexed, docetaxel, Cisplatin micelle injection (HA132) and carboplatin in non-small cell lung cancer (NSCLC), sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoint: Baseline Marker Measurement. Started Jun 2014; status: terminated.
02
Drugs
gemcitabinepemetrexeddocetaxelCisplatin micelle injection (HA132)carboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02145078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02145078.